ESTRO 2024 - Abstract Book

S3927

Physics - Image acquisition and processing

ESTRO 2024

2488

Digital Poster

MRI-based method of AGuiX quantification and correlation with clinical outcomes of the NANOCOL trial

Pauline MAURY 1,2 , Cyrus CHARGARI 1,2 , Michele MONDINI 2 , Sophie BOCKEL 1,2 , Bachir BA 1 , Samy AMMARI 3,4 , Catherine GENESTIE 5 , Sophie ESPENEL 1 , Arthur DARRICAU 2 , Mona SHAHIN 2,6 , Ting-Di WU 7 , François LUX 8 , Olivier TILLEMENT 8 , Géraldine LE DUC 9 , Sandrine DUFORT 9 , Olivier DE BEAUMONT 9 , Fabien BOUX 9 , Daphne MOREL 2 , Sandrine LACOMBE 6 , Eric DEUTSCH 1,2 , Charlotte ROBERT* 1,2 , Erika PORCEL 6 1 Gustave Roussy Cancer Campus, Radiation Oncology, Villejuif, France. 2 Gustave Roussy Cancer Campus, INSERM UMR1030, Villejuif, France. 3 Gustave Roussy Cancer Campus, Imaging, Villejuif, France. 4 ELSAN, Radiology, Sarcelles, France. 5 Gustave Roussy Cancer Campus, Pathology, Villejuif, France. 6 Institut des Sciences Moléculaires d'Orsay, Université Paris Saclay, CNRS, Orsay, France. 7 Institut Curie, CNRS UAR2016 INSERM US43 Multimodal Imaging Center, Orsay, France. 8 Institut Lumière Matière, Université Lyon 1, UMR5306, Villeurbanne, France. 9 NH TherAguiX, SA, Meylan, France

Purpose/Objective:

Clinical trials combining metallic nanoparticles (NPs) with radiotherapy have recently begun. To date, radiotherapy planning does not take into account NPs located in the patients' target volumes. In the framework of the NANOCOL clinical trial (NCT03308604) including 12 patients treated for locally advanced cervical cancers, this study proposes a complete method to evaluate the radiation-induced biological effects of NPs. Quantifications were correlated with clinical results.